Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial

G.G. Wulf, B. Altmann, M. Ziepert, F. D'Amore, G. Held, R. Greil, O. Tournilhac, T. Relander, A. Viardot, M. Wilhelm, C. Wilhelm, A. Pezzutto, J.M. Zijlstra, E. Van Den Neste, P.J. Lugtenburg, J.K. Doorduijn, M. van Gelder, G.W. van Imhoff, F. Zettl, F. BraulkeM. Nickelsen, B. Glass, A. Rosenwald, P. Gaulard, M. Loeffler, M. Pfreundschuh, N. Schmitz, L. Trumper, ACT-2 Study Investigators

Research output: Contribution to journalArticleAcademicpeer-review

14 Citations (Web of Science)
Original languageEnglish
Pages (from-to)143-155
Number of pages13
JournalLeukemia
Volume35
Issue number1
DOIs
Publication statusPublished - 1 Jan 2021

Keywords

  • cd52 expression
  • chemotherapy
  • detude-des-lymphomes
  • epstein-barr-virus
  • lymphoproliferative disorders
  • non-hodgkin-lymphoma
  • phase-ii
  • prognostic-factors
  • prophylaxis
  • therapy
  • PROGNOSTIC-FACTORS
  • PHASE-II
  • CHEMOTHERAPY
  • PROPHYLAXIS
  • THERAPY
  • NON-HODGKIN-LYMPHOMA
  • DETUDE-DES-LYMPHOMES
  • LYMPHOPROLIFERATIVE DISORDERS
  • EPSTEIN-BARR-VIRUS
  • CD52 EXPRESSION

Cite this